Atrion (NASDAQ:ATRI) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Atrion (NASDAQ:ATRI) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the medical instruments supplier’s stock.

Atrion Stock Performance

Shares of ATRI stock opened at $459.92 on Thursday. The stock has a market cap of $809.46 million, a P/E ratio of 43.23 and a beta of 0.69. The stock has a 50 day simple moving average of $458.90 and a 200 day simple moving average of $444.77. Atrion has a 1 year low of $274.98 and a 1 year high of $503.24.

Atrion (NASDAQ:ATRI) last issued its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter. The business had revenue of $48.77 million during the quarter. Atrion had a return on equity of 7.75% and a net margin of 10.60%.

Institutional Investors Weigh In On Atrion

Several institutional investors have recently made changes to their positions in the stock. Kayne Anderson Rudnick Investment Management LLC lifted its stake in Atrion by 1.0% during the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 205,393 shares of the medical instruments supplier’s stock worth $92,926,000 after purchasing an additional 2,111 shares during the last quarter. Vanguard Group Inc. lifted its stake in Atrion by 0.4% during the first quarter. Vanguard Group Inc. now owns 84,876 shares of the medical instruments supplier’s stock worth $39,344,000 after purchasing an additional 326 shares during the last quarter. Glazer Capital LLC bought a new stake in Atrion during the second quarter worth $24,376,000. Bank of New York Mellon Corp lifted its stake in Atrion by 3.0% during the second quarter. Bank of New York Mellon Corp now owns 14,921 shares of the medical instruments supplier’s stock worth $6,751,000 after purchasing an additional 436 shares during the last quarter. Finally, Sagefield Capital LP bought a new stake in Atrion during the second quarter worth $4,859,000. 66.19% of the stock is currently owned by institutional investors.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.